Theranexus SA Market Cap ($48.02 Million)
Market Cap & Net Worth: Theranexus SA (ALTHX)
Theranexus SA market cap. Theranexus SA (PA:ALTHX) has a market capitalization of $48.02 Million (€41.07 Million) as of November 4, 2026. Listed on the PA stock exchange, this France-based company holds position #21889 globally and #343 in its home market, demonstrating a 5.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theranexus SA's stock price €3.33 by its total outstanding shares 14441625 (14.44 Million). Also see ALTHX operating cash flow for how efficiently the company converts equity into cash flow.
Theranexus SA Market Cap History (2017–2026)
Theranexus SA market cap history from 2017 to 2026. Data shows change from $250.72 Million to $56.14 Million (-15.76% CAGR). Check Theranexus SA stock price for real-time trading data and today's change.
Theranexus SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theranexus SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Theranexus SA to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.27x
Theranexus SA's market cap is 4.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $250.72 Million | $147.83K | -$2.11 Million | 1696.01x | N/A |
| 2018 | $302.56 Million | $110.93K | -$5.30 Million | 2727.49x | N/A |
| 2019 | $51.33 Million | $563.85K | -$5.58 Million | 91.03x | N/A |
| 2020 | $314.88 Million | $294.61K | -$4.80 Million | 1068.81x | N/A |
| 2021 | $83.57 Million | $602.00 | -$8.15 Million | 138828.40x | N/A |
| 2022 | $29.55 Million | $414.90K | -$6.57 Million | 71.21x | N/A |
| 2023 | $18.91 Million | $296.33K | -$6.83 Million | 63.81x | N/A |
| 2024 | $9.76 Million | $2.28 Million | -$1.77 Million | 4.27x | N/A |
Competitor Companies of ALTHX by Market Capitalization
Companies near Theranexus SA in the global market cap rankings as of November 4, 2026. Also see Theranexus SA balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Theranexus SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Theranexus SA (2017–2026)
Market capitalization of Theranexus SA from 2017 to today. Between 2017 and today, Theranexus SA's market cap moved from $250.72 Million to $ 56.14 Million, with a yearly change of -15.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €56.14 Million | +55.37% |
| 2025 | €36.13 Million | +270.24% |
| 2024 | €9.76 Million | -48.39% |
| 2023 | €18.91 Million | -36.00% |
| 2022 | €29.55 Million | -64.65% |
| 2021 | €83.57 Million | -73.46% |
| 2020 | €314.88 Million | +513.49% |
| 2019 | €51.33 Million | -83.04% |
| 2018 | €302.56 Million | +20.67% |
| 2017 | €250.72 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Theranexus SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.02 Million USD |
| MoneyControl | $48.02 Million USD |
| MarketWatch | $48.02 Million USD |
| marketcap.company | $48.02 Million USD |
| Reuters | $48.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company… Read more